1. A compound represented by Formula I:
or a pharmaceutically acceptable salt thereof, wherein
X is C\u2014CN;
Cy is
z is hetaryl, \u2014C1-6alkyl-O\u2014C1-6alkyl-, \u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-(hetaryl), \u2014C(O)\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-O\u2014C1-6alkyl-O\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl)-C(O)\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014C0-6alkyl, \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), or \u2014S(O)2\u2014(hetaryl), wherein any of the alkyl, heterocyclyl, or hetaryl optionally is substituted with 1-6 independent halo, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or \u2014C0-6alkyl;
in which the wavy bond is the point of attachment, and wherein the piperazine or morpholine moieties are optionally substituted with 1-6 independent C0-6alkyl groups;
Y is \u2014C(C0-6alkyl)(C0-6alkyl)-, \u2014N(C0-6alkyl)-, \u2014N(C0-6alkyl)-C1-6alkyl-, O, S, >N\u2014C2-6alkyl-N\u2014(C0-6alkyl)(C0-6alkyl), >N\u2014C2-6alkyl-O\u2014C0-6alkyl, >N\u2014C1-6alkyl-C(O)\u2014NH\u2014C0-6alkyl, or >N\u2014C2-6alkyl-N\u2014C(O)\u2014C1-6alkyl; and
R1 is aryl, hetaryl, or heterocyclyl, optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, \u2014C3-10cycloalkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C1-6alkyl-C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or C0-6alkyl; or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy is
3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is aryl optionally substituted with with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the aryl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo or C0-6alkyl.
4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is aryl optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, \u2014C3-10cycloalkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C1-6alkyl-C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or C6alkyl.
5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hetaryl optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the hetaryl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo or C0-6alkyl.
6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hetaryl optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, \u2014C3-10cycloalkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C1-6alkyl-C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or C0-6alkyl.
7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is heterocyclyl optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo or C0-6alkyl.
8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is heterocyclyl optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, \u2014C3-10cycloalkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C1-6alkyl-C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or C0-6alkyl.
9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Y\u2014R1 is
10. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Y is \u2014N(C0-6alkyl)-.
11. A compound represented by Formula I:
a pharmaceutically acceptable salt thereof, wherein
X is C\u2014CN;
Cy is
Z is hetaryl, \u2014C1-6alkyl-O\u2014C1-6alkyl-, \u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-(hetaryl), \u2014C(O)\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-O\u2014C1-6alkyl-O\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl)-C(O)\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014C0-6alkyl, \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), or \u2014S(O)2\u2014(hetaryl), wherein any of the alkyl, heterocyclyl, or hetaryl optionally is substituted with 1-6 independent halo, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or \u2014C0-6alkyl;
or z is
in which the wavy bond is the point of attachment, and wherein the piperazine or morpholine moieties are optionally substituted with 1-6 independent C0-6alkyl groups;
Y is \u2014C(C0-6alkyl)(C0-6alkyl)-, \u2014N(C0-6alkyl)-, \u2014N(C0-6alkyl)-C1-6alkyl-, O, S, >N\u2014C2-6alkyl-N\u2014(C0-6alkyl)(C0-6alkyl), >N\u2014C2-6alkyl-O\u2014C0-6alkyl, >N\u2014C1-6alkyl-C(O)\u2014NH\u2014C0-6alkyl, or >N\u2014C2-6alkyl-N\u2014C(O)\u2014C1-6alkyl;
wherein R1 is selected from the following table:
12. A compound represented by Formula I:
or a pharmaceutically acceptable salt thereof, wherein
X is C\u2014CN;
Cy is
Y is \u2014C(C0-6alkyl)(C0-6alkyl)-, \u2014N(C0-6alkyl)-, \u2014N(C0-6alkyl)-C1-6alkyl-, O, S, >N\u2014C2-6alkyl-N\u2014(C0-6alkyl)(C0-6alkyl), >N\u2014C2-6alkyl-O\u2014C0-6alkyl, >N\u2014C1-6alkyl-C(O)\u2014NH\u2014C0-6alkyl, or >N\u2014C2-6alkyl-N\u2014C(O)\u2014C1-6alkyl; and
R1 is aryl, hetaryl, or heterocyclyl, optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, \u2014C3-10cycloalkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C1-6alkyl-C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or C0-6alkyl;
wherein z is selected from the following table:
13. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Y\u2014R1 is
14. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An image capture apparatus comprising:
an image sensor which outputs an image;
a moving picture image recording instruction unit which issues a first instruction for recording the image obtained by the image sensor as a moving picture image;
a still picture image recording instruction unit which issues a second instruction for recording the image obtained by the image sensor as a still picture image;
a change instruction unit which issues a third instruction for changing a magnification of the image while recording the image as a moving picture image; and
a cancel unit which invalidates the first instruction during a period when the magnification of the image is being changed.
2. The image capture apparatus according to claim 1, further comprising:
an end detection unit which detects an end of changing the magnification of the image; and
a control unit which validates the first instruction when the end detection unit detects the end of changing.
3. The image capture apparatus according to claim 2, further comprising:
a count unit which counts a predetermined time after the end of changing the magnification of the image; and wherein
the control unit validates the first instruction after the count unit has counted the predetermined time.
4. The image capture apparatus according to claim 2, further comprising:
a still picture image recording unit which records the image as a still picture image when the first instruction is issued.
5. The image capture apparatus according to claim 4, further comprising:
a recording instruction detection unit which detects the second instruction during recording of the image as a still picture image by the still picture image recording unit; and
a moving picture image recording unit which records the image after the recording of the image as a still picture image by the still picture image recording unit is completed, when the first instruction is issued.
6. The image capture apparatus according to claim 1, further comprising:
a lens which forms an image on the image sensor;
a driving unit which drives the lens;
an operation control unit which controls operation of the driving unit in accordance with the third instruction;
a sensing unit which senses an operating state of the driving unit; and
a determining unit which determines whether or not the magnification of the image is changed based on the operating state of the driving unit sensed by the sensing unit.
7. An image capture method comprising steps of:
issuing a first instruction for recording an image obtained by an image sensor as a moving picture image;
issuing a second instruction for recording the image obtained by the image sensor as a still picture image;
issuing a third instruction for changing a magnification of the image while recording the image as a moving picture image; and
invalidating the first instruction during a period when the magnification of the image is being changed.
8. The image capture method according to claim 7, further comprising steps of:
detecting an end of changing the magnification of the image; and
validating the first instruction when the end of changing is detected.
9. The image capture method according to claim 8, further comprising steps of:
counting a predetermined time after the end of changing the magnification of the image; and wherein the first instruction is validated after the count unit has counted the predetermined time.
10. The image capture method according to claim 8, further comprising steps of:
recording the image as a still picture image when the first instruction is issued.
11. The image capture method according to claim 10, further comprising steps of:
detecting the second instruction during recording of the image as a still picture image; and
recording the image after the recording of the image as a still picture image is completed, when the first instruction is issued.
12. A computer program product configured to store program instructions for execution on a computer system enabling the computer system to perform:
issuing a first instruction for recording an image obtained by an image sensor as a moving picture image;
issuing a second instruction for recording the image obtained by the image sensor as a still picture image;
issuing a third instruction for changing a magnification of the image while recording the image as a moving picture image; and
invalidating the first instruction during a period when the magnification of the image is being changed.
13. The computer program product according to claim 12, enabling the computer system to further perform:
detecting an end of changing the magnification of the image; and
validating the first instruction when the end of changing is detected.
14. The computer program product according to claim 13, enabling the computer system to further perform:
counting a predetermined time after the end of changing the magnification of the image; and wherein the first instruction is validated after the count unit has counted the predetermined time.
15. The computer program product according to claim 13, enabling the computer system to further perform:
recording the image as a still picture image when the first instruction is issued.
16. The computer program product according to claim 15, enabling the computer system to further perform:
detecting the second instruction during recording of the image as a still picture image; and
recording the image after the recording of the image as a still picture image is completed, when the first instruction is issued.
17. An image capture apparatus comprising:
means for outputting an image;
a moving picture image recording instruction means for issuing a first instruction for recording the image obtained by the image outputting means as a moving picture image;
a still picture image recording instruction means for issuing a second instruction for recording the image obtained by the image outputting means as a still picture image;
a change instruction means for issuing a third instruction for changing a magnification of the image while recording the image as a moving picture image; and
a cancel means for invalidating the first instruction during a period when the magnification of the image is being changed.
18. The image capture apparatus according to claim 17, further comprising:
an end detection means for detecting an end of changing the magnification of the image; and
a control means for validating the first instruction when the end detection means detects the end of changing.